GSK plc (GSK) vs Regeneron Pharmaceuticals, Inc. (REGN)
A side-by-side comparison of GSK plc and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 31, 2026. Differences are shown without an overall score or investment verdict.
GSK
GSK plc
$51.69HealthcareDelayed quote: Jul 31, 2026, 4:00 PM EDT
REGN
Regeneron Pharmaceuticals, Inc.
$762.63HealthcareDelayed quote: Jul 31, 2026, 4:00 PM EDT
Total return — GSK vs REGN
growth of $100 · dividends reinvested · last 30yGSK +570.4%REGN +4818.8%REGN compounded faster
Log scale — wide-divergence pair
GSK REGN
GSK vs REGN: by the numbers
- •GSK is the larger company ($103.56B vs $78.57B market cap).
- •GSK trades at the lower trailing earnings multiple (11.52 vs 18.86 P/E), one valuation lens rather than an overall verdict.
- •REGN converts more revenue to profit (27.86% vs 17.76% net margin).
- •REGN grew revenue faster over the past five years (4.64% vs 0.63% CAGR).
- •GSK pays the higher dividend yield (3.45% vs 0.48%).
Metrics side by side
Valuation
| Metric | GSK | REGN |
|---|---|---|
| P/E ratio | 11.52 | 18.86 |
| Forward P/E | 14.59 | 14.62 |
| P/S ratio | 2.40 | 5.24 |
| P/B ratio | 3.41 | 2.10 |
| PEG ratio | 0.02 | 3.38 |
| EV / EBITDA | 8.56 | 19.81 |
| FCF yield | 7.93% | 4.62% |
Profitability
| Metric | GSK | REGN |
|---|---|---|
| Gross margin | 72.67% | 88.11% |
| Operating margin | 25.65% | 24.74% |
| Net margin | 17.76% | 27.86% |
| ROE | 25.19% | 11.15% |
| ROIC | 16.61% | 8.51% |
Dividends
| Metric | GSK | REGN |
|---|---|---|
| Dividend yield | 3.45% | 0.48% |
| Payout ratio | 23.66% | 8.45% |
Growth (annualized)
| Metric | GSK | REGN |
|---|---|---|
| Revenue CAGR (5Y) | 0.63% | 4.64% |
| EPS CAGR (5Y) | 14.05% | 5.70% |
| FCF CAGR (5Y) | -0.35% | 17.30% |
| Total return CAGR (5Y) | 9.69% | 5.99% |
Frequently asked
- Which has the lower trailing P/E, GSK or REGN?
- GSK has the lower trailing P/E: GSK trades at 11.52 and REGN at 18.86. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, GSK or REGN?
- Over the past five years, REGN grew revenue faster — GSK at a 0.63% CAGR versus REGN at 4.64%.
- Does GSK or REGN pay a bigger dividend?
- GSK yields 3.45% and REGN yields 0.48% based on trailing dividends and the latest price.
- Is GSK or REGN more profitable?
- REGN runs the higher net margin — GSK at 17.76% versus REGN at 27.86%.
- How have GSK and REGN total returns compared?
- Over the past 10 years, GSK delivered 6.30% and REGN delivered 6.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
GSK P/E ratioRegeneron Pharmaceuticals P/E ratioGSK dividend yieldRegeneron Pharmaceuticals dividend yieldGSK ROERegeneron Pharmaceuticals ROEGSK operating marginRegeneron Pharmaceuticals operating marginGSK revenue growthRegeneron Pharmaceuticals revenue growthGSK free cash flowRegeneron Pharmaceuticals free cash flow
GSK & Regeneron Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 31, 2026.